Integra LifeSciences Reports Strong Q2 Earnings, Reaffirms Full-Year Guidance
Integra LifeSciences (NASDAQ:IART) reported second-quarter revenue of $419 million in July 2026, a slight increase from the prior year. Adjusted earnings per share rose by 24% to $0.56 due to improved operational execution and tariff benefits. The company reaffirmed its full-year guidance for organic revenue growth between 0.8%–3.3%, with adjusted EPS expected in the range of $2.40–$2.50. Specialty Surgery and Neurosurgery segments showed positive performance, while Tissue Reconstruction and ENT continued to face challenges. CFO Lea Knight noted that gross margin improved to 61.3% due to manufacturing efficiencies and lower remediation costs. Operating cash flow also increased significantly to $22.8 million. Integra plans a controlled relaunch of its SurgiMend product in the fourth quarter, though meaningful revenue is not expected until after 2026.
Tickers: $IART
Topics: financial_performance medical_devices operational_efficiency